CAS: 346640-08-2

CCF642

3-(4-Methoxyphenyl)-5-((5-Nitrothiophen-2-Yl)Methylene)-2-Thioxothiazolidin-4-One

CCF-642 is a synthetic antimicrobial compound designed for use in laboratory and clinical research settings. It is derived through chemical synthesis, utilizing a combination of heterocyclic structures and functional groups that enhance its activity against a range of bacterial pathogens. CCF-642 operates by disrupting bacterial cell wall synthesis, interfering with peptidoglycan cross-linking, which ultimately leads to cell lysis and death. It maintains efficacy in both gram-positive and gram-negative bacteria, making it a versatile tool in microbiological studies. Primarily, CCF-642 is employed in research devoted to understanding bacterial resistance mechanisms and testing its effectiveness in comparison with existing antibiotics. This includes applications in in-vitro assays and preclinical trials to evaluate its potential as a scaffold for developing new drugs. Its comprehensive activity profile offers a valuable asset in expanding the arsenal against drug-resistant bacterial strains. Scientists utilize CCF-642 in various experimental frameworks to explore novel pathways for antimicrobial interventions, providing insights that drive innovation in antibiotic development.

CCF642 (AC1LYELL) is a novel PDI-inhibiting compound with antimyeloma activity.